Gyre Therapeutics, Inc. Deferred Rent Credit, Noncurrent
Gyre Therapeutics, Inc. (GYRE) had Deferred Rent Credit, Noncurrent of $174.00 thousand as of 2018-12-31, per its 10-K filed 2020-02-20.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:DeferredRentCreditNoncurrent · last filed 2020-02-20
- 2018-12-31: Deferred Rent Credit, Noncurrent $174.00K.
- 2018-09-30: Deferred Rent Credit, Noncurrent $161.00K.
- 2018-06-30: Deferred Rent Credit, Noncurrent $140.00K.
- 2018-03-31: Deferred Rent Credit, Noncurrent $135.00K.
| Period end | Deferred Rent Credit, Noncurrent |
|---|---|
| 2018-12-31 | $174.00K 10-K · filed 2020-02-20 |
| 2018-09-30 | $161.00K 10-Q · filed 2018-11-01 |
| 2018-06-30 | $140.00K 10-Q · filed 2018-08-02 |
| 2018-03-31 | $135.00K 10-Q · filed 2018-05-03 |
| 2016-12-31 | $7.00K 10-K · filed 2018-03-19 |
| 2016-09-30 | $18.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $29.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $40.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $48.00K 10-K · filed 2017-03-08 |
| 2013-12-31 | $26.31K 8-K/A · filed 2015-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |